Wavefront-guided LASIK for the correction of high compound astigmatism and myopic astigmatism

Session Details

Session Title: LASIK Outcomes and Complications

Session Date/Time: Tuesday 10/10/2017 | 16:30-18:00

Paper Time: 16:48

Venue: Room 3.1

First Author: : F.Sousa Neves PORTUGAL

Co Author(s): :    L. Figueiredo   J. Costa   R. Rothwell   C. Arede           

Abstract Details

Purpose:

To evaluate refractive and visual outcomes of the correction of high compound astigmatism and myopic astigmatism with LASIK using Zyoptix® Personalized Treatment Advanced

Setting:

Department of Ophthalmology of Centro Hospitalar Vila Nova de Gaia/Espinho.

Methods:

In this retrospective study we reviewed all patients with high compound astigmatism and myopic astigmatism submitted to LASIK using Zyoptix® Personalized algorithm between 2008 and 2015. Fifty-two eyes of 37 patients with astigmatism higher than 2.75 dioptres (D) and less than 2.00 D sphere were included. Laser in situ keratomileusis (LASIK) was performed with Technolas 217z100® system (Bausch & Lomb). The LASIK flaps were created using Zyoptix® XP microkeratome (Bausch & Lomb). Visual function, refractive outcomes and higher order aberrations (HOA) were evaluated before and three months after surgery. The changes in astigmatism were analyzed using polar values.

Results:

Three months after surgery, all eyes had a spherical equivalent (SE) within 1.00 D of emmetropia and 79% within 0.50 D. In terms of safety, no eye lost more than one line of best-corrected visual acuity (BCVA). There was a significant undercorrection of astigmatism (-0,47 ± 0,49 D) (p<0,01) and no significant induction of torsion with a mean of 0.00 ± 0.25. Higher order aberrations showed no significant variation.

Conclusions:

Zyoptix® Personalized Treatment Advanced was safe and effective in the treatment of high compound and myopic astigmatism. It provided precise correction of SE, did not induce HOA or rotation of the cylinder axis. However, the algorithm slightly undercorrected the astigmatic component and this subject should be evaluated in future studies

Financial Disclosure:

NONE